Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit ...

COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as drugmakers jostle for advantage in the ...

After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has prevailed in its pursuit of obesity biotech Metsera. The companies agreed to an ...

Pfizer has lived up to its threat of taking legal action to prevent Metsera from slipping out of its grasp, but the obesity biotech also seems up for the fight. Last Thursday brought the bombshell ...

Pfizer now has the required regulatory approval for its $4.9 billion acquisition of obesity drug developer Metsera, but whether and when that deal closes may hinge on the outcome of two lawsuits the ...

Novo Nordisk’s CEO dared Pfizer to bid more if it wanted obesity drug developer Metsera so badly. So Pfizer did, with a $10 billion bid that edges out what the Danish pharmaceutical giant was willing ...

Pfizer said it would acquire weight loss biotech Metsera in a deal valued at up to $7.3 billion, including future payments, as it scrambles to win a slice in the booming obesity drug market. The move ...

Investors once speculated that Pfizer might consider acquiring Viking. Weight loss drugs have represented an enormous growth area for biotech and pharma companies over the past couple of years. Pharma ...

Matthew Herper covers medical innovation — both its promise and its perils. Mergers and acquisitions are a spectator sport. You couldn’t hope for a better match to watch than the competition between ...